Clinical trials: Amyloid Beta Protein
Familial Cold Urticaria
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria.
- Trial name
- NCT00214851
- Testing
- Kineret (anakinra)
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Nova Scotia Health Authority
Obstructive Sleep Apnea, Alzheimer's Disease
Brain Sleep Clearance of Amyloid-Beta Peptides
The 'Amyloid Cascade Hypothesis' posits that the accumulation of a peptide, amyloid beta (Aβ), in the brain is the initiating event in Alzheimer's disease (AD), however, the mechanisms involved are not well understood.
- Trial name
- Brain SCRAPs (NCT02474251)
- Testing
- Continuous positive airway pressure device
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer, Alzheimer Dementia (AD)
Restoring Cervical Lymphatic Drainage in Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with the accumulation of abnormal proteins, including amyloid-beta and tau, in the brain.
- Trial name
- LymphDAD (NCT07854327)
- Testing
- Cervical lymphovenous anastomosis (LVA)
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- University of Siena
Sleep, Alzheimer Disease
Sleep Trial to Prevent Alzheimer's Disease
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
- Trial name
- SToP-AD (NCT04629547)
- Testing
- Suvorexant 20 mg
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Alzheimer Disease, Amyloid Beta-Protein
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission…
- Trial name
- NCT00750282
- Testing
- Florbetaben (BAY94-9172)
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 422 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient
Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer's disease or mild cognitive impairment
- Trial name
- NCT01424436
- Testing
- GSK933776
- Where
- 7 sites in Germany, Sweden
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Hydrocephalus, Normal Pressure, Biochemical Lesions Head Region
Role of Brain Specific Biomarkers in Hydrocephalus
Normal pressure hydrocephalus (NPH) is a neurodegenerative disease of unclear etiology characterized by a clinical trias named after the neurosurgeon Hakim.
- Conditions
- Hydrocephalus, Normal Pressure, Biochemical Lesions Head Region, Brain Damage
- Trial name
- NCT06083233
- Testing
- Lumbar puncture, External lumbar drainage, Ventriculo-peritoneal shunt placement
- Where
- Czechia
- Volunteers
- 32 people
- Sponsor
- University Hospital Hradec Kralove
Alzheimer Disease, Amyloid Beta-Protein
Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from…
- Trial name
- NCT01138111
- Testing
- Florbetaben (BAY94-9172)
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Lantheus Biosciences Ltd.
Stress, Ageing
The Relaxation vs. Retreat Study
The purpose of this research study is to examine whether a short term meditation intervention can improve health, mood, and biological markers of cellular stress and aging in novice and experienced meditators compared to controls.
- Conditions
- Stress, Ageing, Wellbeing
- Trial name
- R&R (NCT01857830)
- Testing
- Meditation Retreat, Active Comparator Relaxation Group
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer Disease
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV51, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- NCT00556660
- Testing
- [123I] AV-151
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease, Dementia
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with Alzheimer disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05527288
- Testing
- Drug: [18F]florbetaben
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer Disease
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
- Trial name
- NCT05728736
- Testing
- Lemborexant 25 mg
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Brendan Lucey
Alzheimer Disease
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-308, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00544453
- Testing
- [123I] MNI-308
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor [donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)] for at least 3 months, and…
- Trial name
- NCT00551161
- Testing
- memantine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwell Health
Healthy Aging, Brain Health
Assessing the Influence of Habitual Beef Intake on Key Molecular Markers of Brain Health
his study investigates whether eating lean beef every day can help support brain health and healthy aging in older adults. As people age, protecting memory and cognitive function becomes increasingly important.
- Conditions
- Healthy Aging, Brain Health, Cardiometabolic Health, Normal Aging
- Trial name
- NCT07623785
- Testing
- Lean Beef, Non-Beef Control
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- South Dakota State University
Alzheimer Disease
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
- Trial name
- NCT01978548
- Testing
- JNJ-54861911 10 mg, JNJ-54861911 50 mg
- Where
- 10 sites in Belgium, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00968097
- Testing
- 123-I MNI-340
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers
Beta amyloid immunoreactivity is probably due to a significant number of Ab catabolites corresponding to N-terminally truncated and Cterminally truncated or extended forms which display distinct propensity to aggregation.
- Trial name
- NCT01128725
- Testing
- Alzhamyd
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Alzheimer s Disease, Major Depressive Disorder (MDD)
VR Pupillometry in Cognitive Impairment
With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important.
- Conditions
- Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia
- Trial name
- NCT07402356
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Max-Planck-Institute of Psychiatry